Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, has a very poor prognosis with a median overall survival of 15 months despite of aggressive therapy including surgery, chemotherapy and radiation therapy. New therapy options are urgently needed. Targeted alpha therapy with the short range, high LET alpha emitter 213Bi offers the potential for selective irradiation of tumors, while minimizing damage to adjacent, functional critical areas of the brain. The peptide carrier substance P is targeting neurokinin type 1 (NK-1) receptors, which are consistently over-expressed on glioblastoma cells. Here we report the first clinical experience with 213Bi-labeled DOTA-Substance P in patients with recurrent GBM.
MORGENSTERN Alfred;
KROLICKI Leszek;
KUNIKOWSKA Jolanta;
KOCIARA Henryk;
KROLICKI B;
JAKUCINSKI M;
MIKOŁAJCZAK Renata;
PAWLAK Dariusz;
APOSTOLIDIS Christos;
BRUCHERTSEIFER Frank;
2013-06-14
Oak Ridge National Laboratory
JRC81654
https://register.ornl.gov/2013/TATS/index.shtml,
https://publications.jrc.ec.europa.eu/repository/handle/JRC81654,
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
